<p>Well Health Technologies（多伦多证券交易所代码：WELL）召开了第一季度财报电话会议。请继续阅读会议的主要亮点。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
<p>Well Health Technologies 最近的财报电话会议描绘了一个显著乐观的前景，管理层强调了强劲的收入增长、扩大的利润率和提高的诊所生产力。高管们承认由于资本支出增加和自由现金流疲软而面临压力，但将这些视为有意的、暂时的投资，支撑了对 2026 年目标的重申，以及日益以加拿大初级医疗和人工智能驱动的效率为基础的战略。</p>
<h2>强劲的收入增长和重申的收入目标</h2>
<p>Well Health 第一季度收入为 3.683 亿加元，同比增长 25%，而去年为 2.94 亿加元，诊所和软件平台均为扩张做出了贡献。管理层重申了其 2026 财年的收入展望为 15.5 亿至 16.5 亿加元，意味着报告增长为 11% 至 18%，在排除 Circle Medical 的递延收入后，正常化增长为 16% 至 22%。</p>
<h2>利润率和盈利能力扩张</h2>
<p>盈利能力指标大幅上升，调整后的 EBITDA 同比增长 56%，达到 4310 万加元，调整后的净收入几乎翻倍，达到 1550 万加元。调整后的毛利润增长 39%，达到 1.632 亿加元，调整后的毛利率提高 440 个基点，达到 44.3%，尽管投资加大，但仍显示出运营杠杆的优势。</p>
<h2>加拿大诊所：高增长和更好的利润率</h2>
<p>加拿大诊所第一季度收入为 1.303 亿加元，预计将在 2026 年大幅超过 5 亿加元，巩固了加拿大作为公司增长核心的地位。该部门产生了 1700 万加元的调整后 EBITDA，同比增长 28%，初级医疗的利润率从 6.2% 提高至约 8%，得益于约 47% 的四年收入年复合增长率和 44% 的 EBITDA 年复合增长率。</p>
<h2>运营规模和生产力提升</h2>
<p>系统范围内的患者访问量在第一季度达到 190 万，同比增长 17%，其中加拿大的访问量约为 130 万，增长超过 30%。加拿大的可计费提供者增加 17%，达到 2204 名，每位提供者的访问量大约增加 14%，达到 576 次，表明得益于人工智能工具和数字工作流程，生产力显著提升。</p>
<h2>Wellstar SaaS 动力</h2>
<p>Wellstar，公司的 SaaS 部门，第一季度收入为 2180 万加元，同比增长 27%，每月经常性收入增长 38%，达到 640 万加元。调整后的 EBITDA 达到 490 万加元，增长 14%，如果不考虑与分拆相关的成本，预计将达到约 520 万加元，增长 20%，突显出软件经济的持久性。</p>
<h2>Healwell 的快速扩张和扭转</h2>
<p>Healwell 的收入激增至 3320 万加元，同比增长 316%，反映出积极的扩张和新客户的增加。该部门的调整后 EBITDA 从一年前的 230 万加元亏损转为 70 万加元的盈利，标志着其国际业务的利润率快速恢复，包括在 11 个国家的客户。</p>
<h2>人工智能驱动的产品和运营胜利</h2>
<p>公司强调了其以人工智能为主导的生产力提升，指出在第一季度转录和动用了 195,000 张传真图像的数据，医生通过人工智能转录每周节省了多达 10 小时。Healwell 筛查了超过 59,000 份患者记录以寻找疾病信号，而 Wellstar 的计费平台超过了 10 亿加元的年化医生支付运行率，并保持了接近 80 的 NPS。</p>
<h2>新战略平台和增长举措</h2>
<p>Well Health 推出了其健康智能平台，以统一数据并加速人工智能的部署，旨在优化网络中的成本。公司还推出了 Well Research，以整合临床研究资产，并转向更高利润率的第一阶段试验，并将网络安全能力整合到 CyberWell 中，计划引入外部资本合作伙伴。</p>
<h2>资产负债表强劲和流动性扩张</h2>
<p>公司在季度末拥有 1.34 亿加元的现金和扩展的高级担保贷款额度为 4 亿加元，加上 1 亿加元的可调额度，期限延长至 2030 年。管理层强调，这一举措使借贷能力翻倍，同时在其 NCIB 下继续回购股票，成为其并购驱动增长战略的关键支持。</p>
<h2>大型并购管道和资本配置重点</h2>
<p>Well Health 报告称，其并购管道超过 4.4 亿加元的年收入，涵盖 50 多个目标和超过 125 家诊所，其中约 2.65 亿加元的加拿大诊所收入正在进行深入讨论。公司重申，资本将主要用于加拿大诊所，同时寻求对非核心平台（如 Wellstar、美国资产和 CyberWell）的战略替代方案。</p>
<h2>Circle Medical 合规性和递延收入</h2>
<p>Circle Medical 第一季度收入为 3600 万加元，同比增长 21%，其中包括本季度确认的 1280 万加元的递延收入。管理层指出，由于合规性工作的加强，Circle 的患者访问量同比下降，并预计第二季度仅确认约 480 万加元的递延收入，之后在持续的监管不确定性中不会有进一步的递延。</p>
<h2>资本支出激增和自由现金流压力</h2>
<p>第一季度资本支出同比激增 88%，主要由于 Healwell 整合、诊所升级以及对 Well Research、CyberWell 和智能平台的投资。这些增长项目导致归属于股东的经营调整后自由现金流从 1180 万加元下降至 160 万加元，管理层将这一急剧下降视为暂时的权衡。</p>
<h2>美国资产审查和业绩挑战</h2>
<p>该公司的美国投资组合仍在战略审查中，这给 Wisp、Circle Medical 和 CRH 等业务的时机和结果带来了不确定性。Wisp 的收入大致持平，为 2910 万美元，调整后的 EBITDA 亏损为 90 万美元，而 CRH 的收入略微下降至 1.113 亿美元，反映出员工波动和表现疲软。</p>
<h2>投资驱动的利润压力和执行风险</h2>
<p>短期盈利能力受到对 Well Research、CyberWell 和 AI 平台的支出限制，这抑制了当前的自由现金流。管理层押注于这些举措将随着时间的推移扩大利润率，但承认如果收益到达的时间晚于预期或整合过程更复杂，则存在执行风险。</p>
<h2>对递延收入和并购整合的依赖</h2>
<p>公司的指引包括大约 1760 万美元的 Circle Medical 递延收入，几乎完全贡献 EBITDA，这提高了对时机和可比性的敏感性。管理层还强调了整合超过 4.4 亿美元潜在并购的运营挑战，指出过去在诊所吸收方面的限制，以及需要扩大转型团队以避免过度扩展。</p>
<h2>指引和展望</h2>
<p>Well Health 重申其 2026 年的展望，预计收入为 15.5 亿至 16.5 亿美元，调整后的 EBITDA 为 1.75 亿至 1.85 亿美元，包括剩余的 Circle 递延收入，但仅限于已宣布的交易。管理层预计 Circle 相关的递延收入将在 2026 年大部分到期，目标是调整后的 EBITDA 和自由现金流年增长超过 10%，并计划在大约一年内使其加拿大业务的收入达到约 8 亿美元，调整后的 EBITDA 超过 1 亿美元，这得益于下半年的成本优化推动。</p>
<p>Well Health 的财报电话会议最终在信心与坦诚之间取得了平衡，加拿大诊所、SaaS 和 AI 驱动的业务的强劲增长与美国资产的疲软和短期现金压力形成对比。对于投资者而言，故事的关键在于管理层能否将其重大的投资周期和雄心勃勃的并购管道转化为持续的利润扩张和现金生成，而不在合规、整合或执行风险上绊倒。</p>

WELL

<p>Well Health Technologies（多伦多证券交易所代码：WELL）公布了强劲的第一季度财报，收入同比增长 25%，达到 3.683 亿美元。公司重申了 2026 年收入目标为 15.5 亿至 16.5 亿美元。调整后的息税折旧摊销前利润（EBITDA）增长 56%，达到 4310 万美元，调整后的净收入几乎翻倍，达到 1550 万美元。加拿大诊所的收入为 1.303 亿美元，利润率有所改善。公司强调了基于人工智能的生产力提升，并推出了新的战略平台。Well Health 在本季度末拥有 1.34 亿美元现金，以及超过 4.4 亿美元年收入的强大并购管道</p>

<p>Well Health Technologies ((TSE:WELL)) has held its Q1 earnings call. Read on for the main highlights of the call.</p>
<div class="lb-trans"><p>Well Health Technologies（多伦多证券交易所代码：WELL）召开了第一季度财报电话会议。请继续阅读会议的主要亮点。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
</div><p>Well Health Technologies’ latest earnings call painted a notably upbeat picture, with management emphasizing strong revenue growth, expanding margins and rising clinic productivity. Executives acknowledged pressure from higher capital spending and weaker free cash flow, yet framed these as deliberate, temporary investments that underpin reaffirmed 2026 targets and a strategy increasingly anchored in Canadian primary care and AI-driven efficiency.</p>
<div class="lb-trans"><p>Well Health Technologies 最近的财报电话会议描绘了一个显著乐观的前景，管理层强调了强劲的收入增长、扩大的利润率和提高的诊所生产力。高管们承认由于资本支出增加和自由现金流疲软而面临压力，但将这些视为有意的、暂时的投资，支撑了对 2026 年目标的重申，以及日益以加拿大初级医疗和人工智能驱动的效率为基础的战略。</p>
</div><h2>Strong Top-Line Growth and Reaffirmed Revenue Targets</h2>
<div class="lb-trans"><h2>强劲的收入增长和重申的收入目标</h2>
</div><p>Well Health posted Q1 revenue of $368.3 million, up 25% year over year from $294 million, as both clinics and software platforms contributed to the expansion. Management reaffirmed its fiscal 2026 revenue outlook of $1.55 billion to $1.65 billion, implying reported growth of 11% to 18% and normalized growth of 16% to 22% when excluding Circle Medical’s deferred revenue.</p>
<div class="lb-trans"><p>Well Health 第一季度收入为 3.683 亿加元，同比增长 25%，而去年为 2.94 亿加元，诊所和软件平台均为扩张做出了贡献。管理层重申了其 2026 财年的收入展望为 15.5 亿至 16.5 亿加元，意味着报告增长为 11% 至 18%，在排除 Circle Medical 的递延收入后，正常化增长为 16% 至 22%。</p>
</div><h2>Margin and Profitability Expansion</h2>
<div class="lb-trans"><h2>利润率和盈利能力扩张</h2>
</div><p>Profitability metrics moved sharply higher, with adjusted EBITDA rising 56% year over year to $43.1 million and adjusted net income nearly doubling to $15.5 million. Adjusted gross profit climbed 39% to $163.2 million, lifting adjusted gross margin by 440 basis points to 44.3%, underscoring operating leverage despite heavier investment.</p>
<div class="lb-trans"><p>盈利能力指标大幅上升，调整后的 EBITDA 同比增长 56%，达到 4310 万加元，调整后的净收入几乎翻倍，达到 1550 万加元。调整后的毛利润增长 39%，达到 1.632 亿加元，调整后的毛利率提高 440 个基点，达到 44.3%，尽管投资加大，但仍显示出运营杠杆的优势。</p>
</div><h2>Canadian Clinics: High Growth and Better Margins</h2>
<div class="lb-trans"><h2>加拿大诊所：高增长和更好的利润率</h2>
</div><p>Canadian clinics delivered $130.3 million in Q1 revenue and are on pace to materially exceed $500 million in 2026, reinforcing Canada as the company’s growth core. This segment generated $17 million of adjusted EBITDA, up 28% year over year, with primary care margins improving to roughly 8% from 6.2%, supported by a four-year revenue CAGR of about 47% and EBITDA CAGR of 44%.</p>
<div class="lb-trans"><p>加拿大诊所第一季度收入为 1.303 亿加元，预计将在 2026 年大幅超过 5 亿加元，巩固了加拿大作为公司增长核心的地位。该部门产生了 1700 万加元的调整后 EBITDA，同比增长 28%，初级医疗的利润率从 6.2% 提高至约 8%，得益于约 47% 的四年收入年复合增长率和 44% 的 EBITDA 年复合增长率。</p>
</div><h2>Operational Scale and Productivity Gains</h2>
<div class="lb-trans"><h2>运营规模和生产力提升</h2>
</div><p>System-wide patient visits reached 1.9 million in Q1, up 17% year over year, with Canadian visits around 1.3 million growing more than 30%. Billable providers in Canada increased 17% to 2,204, and visits per provider rose roughly 14% to 576, indicating meaningful productivity gains helped by AI tools and digital workflows.</p>
<div class="lb-trans"><p>系统范围内的患者访问量在第一季度达到 190 万，同比增长 17%，其中加拿大的访问量约为 130 万，增长超过 30%。加拿大的可计费提供者增加 17%，达到 2204 名，每位提供者的访问量大约增加 14%，达到 576 次，表明得益于人工智能工具和数字工作流程，生产力显著提升。</p>
</div><h2>Wellstar SaaS Momentum</h2>
<div class="lb-trans"><h2>Wellstar SaaS 动力</h2>
</div><p>Wellstar, the company’s SaaS arm, generated $21.8 million in Q1 revenue, up 27% year over year, with monthly recurring revenue advancing 38% to $6.4 million. Adjusted EBITDA reached $4.9 million, up 14%, and would have been about $5.2 million and up 20% excluding spinout-related costs, highlighting durable software economics.</p>
<div class="lb-trans"><p>Wellstar，公司的 SaaS 部门，第一季度收入为 2180 万加元，同比增长 27%，每月经常性收入增长 38%，达到 640 万加元。调整后的 EBITDA 达到 490 万加元，增长 14%，如果不考虑与分拆相关的成本，预计将达到约 520 万加元，增长 20%，突显出软件经济的持久性。</p>
</div><h2>Healwell’s Rapid Scale and Turnaround</h2>
<div class="lb-trans"><h2>Healwell 的快速扩张和扭转</h2>
</div><p>Healwell’s top line surged to $33.2 million, a striking 316% year-over-year increase reflecting aggressive expansion and new customers. The unit swung to positive adjusted EBITDA of $0.7 million from a $2.3 million loss a year ago, signalling rapid margin recovery across its international footprint, including clients across 11 countries.</p>
<div class="lb-trans"><p>Healwell 的收入激增至 3320 万加元，同比增长 316%，反映出积极的扩张和新客户的增加。该部门的调整后 EBITDA 从一年前的 230 万加元亏损转为 70 万加元的盈利，标志着其国际业务的利润率快速恢复，包括在 11 个国家的客户。</p>
</div><h2>AI-Enabled Product and Operational Wins</h2>
<div class="lb-trans"><h2>人工智能驱动的产品和运营胜利</h2>
</div><p>The company stressed its AI-led productivity push, noting that it transcribed and mobilized data from 195,000 fax images in Q1, with physicians reportedly saving up to 10 hours per week through AI transcription. Healwell screened more than 59,000 patient records for disease signals, while Wellstar’s billing platform surpassed a $1 billion annualized physician pay run rate and maintained an NPS near 80.</p>
<div class="lb-trans"><p>公司强调了其以人工智能为主导的生产力提升，指出在第一季度转录和动用了 195,000 张传真图像的数据，医生通过人工智能转录每周节省了多达 10 小时。Healwell 筛查了超过 59,000 份患者记录以寻找疾病信号，而 Wellstar 的计费平台超过了 10 亿加元的年化医生支付运行率，并保持了接近 80 的 NPS。</p>
</div><h2>New Strategic Platforms and Growth Initiatives</h2>
<div class="lb-trans"><h2>新战略平台和增长举措</h2>
</div><p>Well Health launched its Health Intelligence Platform to unify data and accelerate AI deployment, targeting cost optimization across the network. The company also rolled out Well Research to consolidate clinical research assets and shift toward higher-margin Phase I trials, and combined cybersecurity capabilities into CyberWell, where it plans to bring in external capital partners.</p>
<div class="lb-trans"><p>Well Health 推出了其健康智能平台，以统一数据并加速人工智能的部署，旨在优化网络中的成本。公司还推出了 Well Research，以整合临床研究资产，并转向更高利润率的第一阶段试验，并将网络安全能力整合到 CyberWell 中，计划引入外部资本合作伙伴。</p>
</div><h2>Balance Sheet Strength and Liquidity Expansion</h2>
<div class="lb-trans"><h2>资产负债表强劲和流动性扩张</h2>
</div><p>The company ended the quarter with $134 million in cash and an expanded senior secured facility of CAD 400 million plus a CAD 100 million accordion, with maturities extended to 2030. Management highlighted this doubled lending capacity, alongside continued share buybacks under its NCIB, as key supports for its M&amp;A-driven growth strategy.</p>
<div class="lb-trans"><p>公司在季度末拥有 1.34 亿加元的现金和扩展的高级担保贷款额度为 4 亿加元，加上 1 亿加元的可调额度，期限延长至 2030 年。管理层强调，这一举措使借贷能力翻倍，同时在其 NCIB 下继续回购股票，成为其并购驱动增长战略的关键支持。</p>
</div><h2>Large M&amp;A Pipeline and Capital Allocation Focus</h2>
<div class="lb-trans"><h2>大型并购管道和资本配置重点</h2>
</div><p>Well Health reported an M&amp;A pipeline exceeding $440 million of annual revenue across more than 50 targets and over 125 clinics, with about $265 million of Canadian clinic revenue in advanced discussions. The company reiterated that capital will be directed primarily toward Canadian clinics, while pursuing strategic alternatives for non-core platforms such as Wellstar, U.S. assets and CyberWell.</p>
<div class="lb-trans"><p>Well Health 报告称，其并购管道超过 4.4 亿加元的年收入，涵盖 50 多个目标和超过 125 家诊所，其中约 2.65 亿加元的加拿大诊所收入正在进行深入讨论。公司重申，资本将主要用于加拿大诊所，同时寻求对非核心平台（如 Wellstar、美国资产和 CyberWell）的战略替代方案。</p>
</div><h2>Circle Medical Compliance and Deferred Revenue</h2>
<div class="lb-trans"><h2>Circle Medical 合规性和递延收入</h2>
</div><p>Circle Medical posted Q1 revenue of $36 million, up 21% year over year, including $12.8 million of previously deferred revenue recognized in the quarter. Management noted a year-over-year decline in Circle patient visits due to heightened compliance efforts and expects only about $4.8 million of deferred revenue to be recognized in Q2, with no further deferrals thereafter amid ongoing regulatory uncertainty.</p>
<div class="lb-trans"><p>Circle Medical 第一季度收入为 3600 万加元，同比增长 21%，其中包括本季度确认的 1280 万加元的递延收入。管理层指出，由于合规性工作的加强，Circle 的患者访问量同比下降，并预计第二季度仅确认约 480 万加元的递延收入，之后在持续的监管不确定性中不会有进一步的递延。</p>
</div><h2>Capex Surge and Free Cash Flow Pressure</h2>
<div class="lb-trans"><h2>资本支出激增和自由现金流压力</h2>
</div><p>Capital expenditures jumped 88% year over year in Q1, driven by Healwell integration, clinic upgrades and investments in Well Research, CyberWell and the intelligence platform. These growth projects contributed to a drop in operating adjusted free cash flow attributable to shareholders to $1.6 million from $11.8 million, a sharp decline that management framed as a temporary trade-off.</p>
<div class="lb-trans"><p>第一季度资本支出同比激增 88%，主要由于 Healwell 整合、诊所升级以及对 Well Research、CyberWell 和智能平台的投资。这些增长项目导致归属于股东的经营调整后自由现金流从 1180 万加元下降至 160 万加元，管理层将这一急剧下降视为暂时的权衡。</p>
</div><h2>U.S. Assets Under Review and Performance Challenges</h2>
<div class="lb-trans"><h2>美国资产审查和业绩挑战</h2>
</div><p>The company’s U.S. portfolio remains under strategic review, introducing uncertainty around timing and outcomes for businesses such as Wisp, Circle Medical and CRH. Wisp’s revenue was roughly flat at $29.1 million with a $0.9 million adjusted EBITDA loss, while CRH revenue slipped modestly to $111.3 million, reflecting staffing volatility and weaker performance.</p>
<div class="lb-trans"><p>该公司的美国投资组合仍在战略审查中，这给 Wisp、Circle Medical 和 CRH 等业务的时机和结果带来了不确定性。Wisp 的收入大致持平，为 2910 万美元，调整后的 EBITDA 亏损为 90 万美元，而 CRH 的收入略微下降至 1.113 亿美元，反映出员工波动和表现疲软。</p>
</div><h2>Investment-Driven Margin Pressure and Execution Risk</h2>
<div class="lb-trans"><h2>投资驱动的利润压力和执行风险</h2>
</div><p>Near-term profitability has been constrained by spending on Well Research, CyberWell and the AI platform, which depress current free cash flow. Management is betting that these initiatives will expand margins over time, but acknowledged the execution risk if benefits arrive later than expected or integration proves more complex.</p>
<div class="lb-trans"><p>短期盈利能力受到对 Well Research、CyberWell 和 AI 平台的支出限制，这抑制了当前的自由现金流。管理层押注于这些举措将随着时间的推移扩大利润率，但承认如果收益到达的时间晚于预期或整合过程更复杂，则存在执行风险。</p>
</div><h2>Dependence on Deferred Revenue and M&amp;A Integration</h2>
<div class="lb-trans"><h2>对递延收入和并购整合的依赖</h2>
</div><p>The company’s guidance includes approximately $17.6 million of Circle Medical deferred revenue with nearly full EBITDA contribution, which heightens sensitivity to timing and comparability. Management also highlighted the operational challenge of integrating more than $440 million of potential M&amp;A, noting past limits on clinic absorption and the need to scale transformation teams to avoid overextension.</p>
<div class="lb-trans"><p>公司的指引包括大约 1760 万美元的 Circle Medical 递延收入，几乎完全贡献 EBITDA，这提高了对时机和可比性的敏感性。管理层还强调了整合超过 4.4 亿美元潜在并购的运营挑战，指出过去在诊所吸收方面的限制，以及需要扩大转型团队以避免过度扩展。</p>
</div><h2>Guidance and Outlook</h2>
<div class="lb-trans"><h2>指引和展望</h2>
</div><p>Well Health reaffirmed its 2026 outlook for $1.55 billion to $1.65 billion in revenue and $175 million to $185 million in adjusted EBITDA, including the remaining Circle deferrals but only announced deals. Management expects Circle-related deferrals to largely roll off in 2026, targets more than 10% annual growth in adjusted EBITDA and free cash flow, and is aiming for its Canadian operations to reach about $800 million in revenue and over $100 million of adjusted EBITDA within roughly a year, helped by a cost-optimization push in the second half.</p>
<div class="lb-trans"><p>Well Health 重申其 2026 年的展望，预计收入为 15.5 亿至 16.5 亿美元，调整后的 EBITDA 为 1.75 亿至 1.85 亿美元，包括剩余的 Circle 递延收入，但仅限于已宣布的交易。管理层预计 Circle 相关的递延收入将在 2026 年大部分到期，目标是调整后的 EBITDA 和自由现金流年增长超过 10%，并计划在大约一年内使其加拿大业务的收入达到约 8 亿美元，调整后的 EBITDA 超过 1 亿美元，这得益于下半年的成本优化推动。</p>
</div><p>Well Health’s earnings call ultimately balanced confidence with candor, as strong growth in Canadian clinics, SaaS and AI-enabled operations contrasted with weaker U.S. assets and near-term cash strain. For investors, the story hinges on whether management can convert its heavy investment cycle and ambitious M&amp;A pipeline into sustained margin expansion and cash generation without stumbling on compliance, integration or execution risks.</p>
<div class="lb-trans"><p>Well Health 的财报电话会议最终在信心与坦诚之间取得了平衡，加拿大诊所、SaaS 和 AI 驱动的业务的强劲增长与美国资产的疲软和短期现金压力形成对比。对于投资者而言，故事的关键在于管理层能否将其重大的投资周期和雄心勃勃的并购管道转化为持续的利润扩张和现金生成，而不在合规、整合或执行风险上绊倒。</p>
</div>

Well Health Technologies 加大对人工智能和诊所的投入